183 related articles for article (PubMed ID: 37587777)
1. Helical-Like Assembly of Nateglinide as Coating for Oral Delivery of Insulin and Their Synergistic Prevention of Diabetes Mellitus.
Li Y; Chen L; Xu Y; Li S; Yan H; Chen T; Hua Z; Wu D; Zhao R; Hu J
Adv Sci (Weinh); 2023 Oct; 10(29):e2301879. PubMed ID: 37587777
[TBL] [Abstract][Full Text] [Related]
2. Bioinspired pH-Responsive Microalgal Hydrogels for Oral Insulin Delivery with Both Hypoglycemic and Insulin Sensitizing Effects.
Ren C; Zhong D; Qi Y; Liu C; Liu X; Chen S; Yan S; Zhou M
ACS Nano; 2023 Jul; 17(14):14161-14175. PubMed ID: 37406357
[TBL] [Abstract][Full Text] [Related]
3. Charge-switchable zwitterionic polycarboxybetaine particle as an intestinal permeation enhancer for efficient oral insulin delivery.
Li Y; Ji W; Peng H; Zhao R; Zhang T; Lu Z; Yang J; Liu R; Zhang X
Theranostics; 2021; 11(9):4452-4466. PubMed ID: 33754071
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Ikenoue T; Kondo N
Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
7. Development of an M cell targeted nanocomposite system for effective oral protein delivery: preparation, in vitro and in vivo characterization.
Song JG; Lee SH; Han HK
J Nanobiotechnology; 2021 Jan; 19(1):15. PubMed ID: 33422063
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, and evaluation in vivo of Ins-SiO₂-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin.
Zhao X; Shan C; Zu Y; Zhang Y; Wang W; Wang K; Sui X; Li R
Int J Pharm; 2013 Sep; 454(1):278-84. PubMed ID: 23830939
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
10. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
Kitahara Y; Miura K; Takesue K; Mine T; Wada R; Uchida Y; Ito S; Yagihashi S
Metabolism; 2002 Nov; 51(11):1452-7. PubMed ID: 12404197
[TBL] [Abstract][Full Text] [Related]
11. Effect of CAPE-pNO
Li S; Huang Q; Zhang L; Qiao X; Zhang Y; Tang F; Li Z
Eur J Pharmacol; 2019 Jun; 853():1-10. PubMed ID: 30885574
[TBL] [Abstract][Full Text] [Related]
12. Nateglinide.
Dunn CJ; Faulds D
Drugs; 2000 Sep; 60(3):607-615; discussion 616-7. PubMed ID: 11030470
[TBL] [Abstract][Full Text] [Related]
13. Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.
Mori A; Lee P; Yamashita T; Nishimaki Y; Oda H; Saeki K; Miki Y; Mizutani H; Ishioka K; Honjo T; Arai T; Sako T
Vet Res Commun; 2009 Dec; 33(8):957-70. PubMed ID: 19728131
[TBL] [Abstract][Full Text] [Related]
14. Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance.
Tanabe K; Liu Z; Patel S; Doble BW; Li L; Cras-Méneur C; Martinez SC; Welling CM; White MF; Bernal-Mizrachi E; Woodgett JR; Permutt MA
PLoS Biol; 2008 Feb; 6(2):e37. PubMed ID: 18288891
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
16. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
17. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
18. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
Sato Y; Nishikawa M; Shinkai H; Sukegawa E
Diabetes Res Clin Pract; 1991 Apr; 12(1):53-9. PubMed ID: 1906797
[TBL] [Abstract][Full Text] [Related]
19. Xanthosine, a purine glycoside mediates hepatic glucose homeostasis through inhibition of gluconeogenesis and activation of glycogenesis via regulating the AMPK/ FoxO1/AKT/GSK3β signaling cascade.
Ahmed SA; Sarma P; Barge SR; Swargiary D; Devi GS; Borah JC
Chem Biol Interact; 2023 Feb; 371():110347. PubMed ID: 36627075
[TBL] [Abstract][Full Text] [Related]
20. A Nanocomposite Vehicle Based on Metal-Organic Framework Nanoparticle Incorporated Biodegradable Microspheres for Enhanced Oral Insulin Delivery.
Zhou Y; Liu L; Cao Y; Yu S; He C; Chen X
ACS Appl Mater Interfaces; 2020 May; 12(20):22581-22592. PubMed ID: 32340452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
